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Overview
Background
Oral hairy leukoplakia (OHL) is a disease of the mucosa first described in 1984. This pathology is
associated with Epstein-Barr virus (EBV) and occurs mostly in people with HIV infection, both
immunocompromised and immunocompetent, and can affect patients who are HIV negative.{ref1}{ref2}
The first case in an HIV-negative patient was reported in 1999 in a 56-year-old patient with acute
lymphocytic leukemia. Later, many cases were reported in heart, kidney, and bone marrow transplant
recipients and patients with hematological malignancies.{ref3}{ref4}

Pathophysiology
The Epstein-Barr virus (EBV), a ubiquitous herpesvirus estimated to infect 90% of the world's population,
is linked to a growing number of diseases, especially in immunocompromised hosts. Like all
herpesviruses, EBV establishes a life-long, persistent infection of its host. The pathogenesis of hairy
leukoplakia is clearly complex, potentially requiring a convergence of factors including EBV co-infection,
productive EBV replication, EBV genetic evolution, expression of specific EBV "latent" genes, and
immune escape. All of these factors are likely facilitated by local and systemic host
immunodeficiency.{ref5}
EBV initially infects basal epithelial cells in the pharynx, where it enters a replicative state leading to the
release of infectious virus into the saliva throughout the life of the infected person. In the pharynx, the
virus also enters B cells, where it persists indefinitely in a latent state. Cytotoxic T lymphocytes cannot
eliminate EBV from the body, but they are essential in maintaining the latent state of the infection. In
states of immune dysfunction in which the number of EBV-specific cytotoxic T lymphocytes is decreased,
there is an increase in the number of circulating EBV-infected B cells.
In addition, a marked decrease or an absence of Langerhans cells occurs in hairy leukoplakia biopsy
tissues.{ref6}{ref7} Langerhans cells are the antigen-presenting immune cells that are required for an
immune system response to the viral infection and their deficiency may permit EBV to persistently
replicate and escape immune recognition.

Epidemiology
Frequency
United States
Hairy leukoplakia is one of the most common virally induced, oral diseases of HIV-infected individuals,
with a point prevalence as high as 25-53%.{ref8} The 6-year incidence of oral hairy leukoplakia (OHL) in
this patient population was reported to be around 32%. A significant trend to a lower prevalence of oral
hairy leukoplakia was observed in the group of patients who were already taking antiretroviral therapy,
non–highly active antiretroviral therapy (HAART) and HAART (P <.001 and P = .004, respectively).{ref9}
Fewer cases of oral hairy leukoplakia were reported in non-HIV–infected patients. This is probably due to
underdiagnosis and underreporting of this disease in patients with hematological malignancies or solid
organ transplantation. Some studies showed the prevalence of oral hairy leukoplakia in renal transplant
recipients to be more than 11%.{ref10}

International
The incidence of oral hairy leukoplakia is similar to that in the United States and thereby reflects the
prevalence of HIV. In populations where the prevalence of HIV is low, oral mucosal lesions alone are poor
prognostic predictors of HIV infection.{ref11}
A cross-sectional study from Brazil reported on data collected from clinical examinations, interviews, and
medical records for adult patients treated an HIV/AIDS clinic at the University Hospital of the Federal
University in Rio Grande. Three hundred persons were observed (April 2006 to January 2007). Of these
patients, 51% were male and the mean age was 40 years. Thirty-nine percent presented with oral lesions.
The most common was candidiasis (59.1%), followed by hairy leukoplakia (19.5%).{ref12}
A study from Saudi Arabia reported that compared with age and sex-matched healthy control subjects (N
= 52), 8.6% of stable renal transplantation patients (N = 58) had oral leukoplakia. Other oral lesions
reported were gingival hyperplasia (74.1%) and erythematous candidiasis (15.5%).{ref13} However, a
study from Spain reported only one case of hairy leukoplakia in 500 renal transplant recipients
studied.{ref14}

Race
No racial predilection has been established for oral hairy leukoplakia.

Sex
Oral hairy leukoplakia is most commonly observed in homosexual men who are HIV positive, especially in
those who smoke.

Age
No age predilection has been established for oral hairy leukoplakia.

Prognosis
The majority of patients with oral hairy leukoplakia (OHL) tend to have significant immunosuppression at
the time of diagnosis. Oral hairy leukoplakia occurs relatively soon after HIV seroconversion, typically
before AIDS. Median CD4 count when oral hairy leukoplakia is first detected is 235-468/µL. Another study
showed oral hairy leukoplakia occurred mostly in patients with CD4 counts of 200-500/µL.{ref15}
In patients with HIV, the median CD4 count when oral hairy leukoplakia is first detected is 468/µL. If these
patients do not have AIDS-defining disease at the time oral hairy leukoplakia is diagnosed, the probability
of developing AIDS if not receiving highly active antiretroviral therapy (HAART) is 48% by 16 months and
83% at 31 months. In addition, studies have shown that patients with AIDS with oral hairy leukoplakia
have a shorter lifespan than those who do not present this lesion. Furthermore, if these patients are
concomitantly co-infected with hepatitis B virus, the risk of early progression to AIDS increases 4-fold.
Further studies in HIV-seropositive patients show that the median survival after the diagnosis of oral hairy
leukoplakia is around 20 months. In patients with CD4 count greater than or equal to 300/μL, oral hairy
leukoplakia is associated with median survival time of 25 months, compared with 52 months in patients
with normal counts.{ref16}

Presentation

History
Patients with oral hairy leukoplakia (OHL) may report a nonpainful white plaque along the lateral tongue
borders. The appearance may change daily. The natural history of hairy leukoplakia is variable. Lesions
may frequently appear and disappear spontaneously. Hairy leukoplakia is often asymptomatic, and many
patients are unaware of its presence. Some patients with hairy leukoplakia do experience symptoms
including mild pain, dysesthesia, alteration of taste, and the psychological impact of its unsightly cosmetic
appearance.

Physical Examination
Unilateral or bilateral nonpainful white lesions can be seen on the margins, dorsal or ventral surfaces of
the tongue, or on buccal mucosa, as shown in the image below. Oral hairy leukoplakia (OHL) lesions may
vary in appearance from smooth, flat, small lesions to irregular "hairy" or "feathery" lesions with prominent
folds or projections.

Lateral tongue in oral hairy leukoplakia.
{file63311}
Lesions may be either continuous or discontinuous along both tongue borders, and they are often not
bilaterally symmetric. Lesions are adherent, and only the most superficial layers can be removed by
scraping. There is no associated erythema or edema of the surrounding tissue. Hairy leukoplakia may
also involve dorsal and ventral tongue surfaces, the buccal mucosa, or the gingiva. On the ventral tongue,
buccal mucosa, or gingiva, the lesion may be flat and smooth, lacking the characteristic "hairy"
appearance.{ref2}
See the image below.

Oral leukoplakia.
{file28244}

Causes
Oral hairy leukoplakia (OHL) has been associated with HIV infection and/or immunosuppression.{ref17}
The risk of developing oral hairy leukoplakia doubles with each 300-unit decrease in CD4 count. A high
viral load was strongly associated to the oral lesions occurrence independently of CD4 + cell count.{ref8}
More recently, it has been described in patients with other forms of severe immunodeficiency including
those associated with chemotherapy, organ transplant, and leukemia. Rarely, it may occur in patients
who are immunocompetent.
Oral hairy leukoplakia also has been described in association with Behçet syndrome and ulcerative colitis.
Smoking more than a pack of cigarettes a day is positively correlated with the development of oral hairy
leukoplakia in HIV-positive men.
No increase in oral hairy leukoplakia was observed when controlled for number of oral sex partners.

Complications
The complication associated with oral hairy leukoplakia (OHL) is an occasional candidal superinfection,
which often results in an uncomfortable glossopyrosis (burning tongue).
Altered taste sensation is a rare complication.
The presence of oral lesions has a significant impact on health-related quality of life, because oral health
is associated with physical and mental health.{ref18}
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Diagnostic Considerations
Also consider the following:


Geographic tongue



Frictional keratosis



Squamous cell carcinoma



Lichen planus



Tobacco-associated leukoplakia



Pseudo–hairy leukoplakia



Human papillomavirus (HPV)–induced neoplasia



Syphilitic mucous patch



Idiopathic leukoplakia



White sponge nevus



Hyperplastic candidiasis

White sponge nevus, candidiasis, or thrush typically occurs as a flat lesion, removable by scraping, which reveals an
erythematous base. However, hyperplastic candidiasis lesions are adherent and do not wipe off, making this disease
especially difficult to distinguish from oral hairy leukoplakia (OHL). Resolution of the lesion with antifungal
therapy suggests candidiasis over hairy leukoplakia. However, hairy leukoplakia lesions are commonly also infected
with Candida, further confusing the clinical diagnosis. See the images below.

White sponge nevus.
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Hyperplastic candidiasis.
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Frictional keratosis typically occurs on the lateral borders of the tongue as a consequence of tongue biting by the
molar teeth or some other abrasive irritant (eg, from rubbing upon poorly fitting dental work), as shown in the image
below. This lesion should quickly resolve after removal of the provoking stimulus.

Morsicatio linguarum, or tongue biting.

{file63312}
Tobacco-induced leukoplakia occurs in smokers and individuals who chew tobacco. These lesions are typically not
shaggy like hairy leukoplakia, and they may occur anywhere in the oral cavity. They are often premalignant and
should be evaluated by biopsy and histologic examination. See the image below.

Ventral tongue in oral leukoplakia.
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Lichen planus or lichenoid eruptions occur as autoimmune or allergic reactions to an unknown stimulus. In HIVinfected patients, lichen planus often occurs on the buccal mucosa, typically with a reticulated pattern. Oral lichen
planus may also be associated with cutaneous lesions. See the image below.

Lateral tongue in lichen planus.

{file63314}
Lesions that clinically and histologically mimicked oral hairy leukoplakia but were not associated with EBV
infection have been characterized as pseudo–hairy leukoplakia.
Proliferative verrucous leukoplakia can have a papillary and roughened surface, which may simulate the corrugated
surface of oral hairy leukoplakia. Proliferative verrucous leukoplakia is known for malignant transformation. The
two examples on the tongue and gingiva in the images below showed squamous cell carcinoma with biopsy.

Proliferative verrucous leukoplakia of the lateral tongue; biopsy showed squamous cell carcinoma.

{file63336}

Proliferative verrucous leukoplakia of the gingiva; biopsy showed squamous cell carcinoma.

{file63337}

Differentials
Candidiasis
Condyloma Acuminatum
Morsicatio buccarum, labiorum, and linguarum

Cheek, lip, and tongue biting
Oral Frictional Hyperkeratosis
Oral Leukoplakia
Proliferative Verrucous Leukoplakia
White sponge nevus

Workup
Laboratory Studies
In most cases of oral hairy leukoplakia (OHL), the diagnosis is established on clinical basis, while a
definitive diagnosis requires both an appropriate histopathological appearance and the demonstration of
Epstein-Barr virus (EBV) DNA, RNA, or protein within the epithelial cells of the lesion.
Several immunohistochemical and in situ hybridization kits are commercially available for this
purpose.{ref19} Tissue biopsy is indicated only if the lesions are unusual in appearance or ulcerated and
suggest cancer.

Procedures
It is important to differentiate hairy leukoplakia from other, more serious, oral lesions that may have a
similar clinical appearance. In some cases, biopsy and histologic examination are required to exclude
cancer.

Histologic Findings
The histopathology of oral hairy leukoplakia (OHL) is characterized by the following five major features:


Hyperkeratosis of the upper epithelial layer that represents an altered pattern of keratin expression in
the squamous epithelial cells: This hyperkeratosis is largely responsible for the characteristic shaggy
or "hairy" gross appearance of the lesion. Superficial infections of the hyperkeratinized epithelium
with bacteria or Candida may also be seen.



Parakeratosis of the superficial epithelial layer: This abnormal persistence of cell nuclei in the
superficial epithelial layers may represent incomplete squamous differentiation.



Acanthosis of the stratum spinosum in the epithelial mid layer: This abnormal expansion of cells
occurs with foci or layers of ballooning koilocyte-like cells. The nuclei have a homogenous groundglass appearance and may contain Cowdry type A intranuclear inclusions.



Minimal or no inflammation in the epithelial and subepithelial tissues



Histologically normal basal epithelial layer

Although these characteristic histologic features of hairy leukoplakia are highly suggestive of the
diagnosis, none is unique to the lesion. Thus, a definitive diagnosis of hairy leukoplakia requires both an
appropriate histologic/cytologic appearance and demonstration of Epstein-Barr virus (EBV) DNA, RNA, or
protein within the epithelial cells of the lesion.

Treatment
Medical Care
As a benign lesion with low morbidity, oral hairy leukoplakia (OHL) does not require specific treatment in
every case. Indications for treatment include symptoms attributable to the lesion, or a patient's desire to
eliminate the lesion for cosmetic reasons. The variable natural history of the lesion and its tendency
toward spontaneous resolution should be considered in any management decision. Several treatment
options are available.
Systemic antiviral therapy usually achieves resolution of the lesion within 1-2 weeks of therapy.{ref20}
Oral therapy with acyclovir requires high doses (800 mg 5 times per day) to achieve therapeutic
levels.{ref21} Valacyclovir (1000 mg 3 times a day) and famciclovir (500 mg 3 times a day) are newer
antiviral drugs with higher oral bioavailability than acyclovir and can be dosed less often. Antiviral drugs
inhibit productive Epstein-Barr virus (EBV) replication but do not eliminate the latent state of infection.
Hairy leukoplakia often recurs several weeks after the cessation of antiviral therapy.
Topical therapy with podophyllin resin 25% solution usually achieves resolution after 1-2 treatment
applications. The treatments may temporarily cause local pain, discomfort, and alteration of taste.
Podophyllin has cellular cytotoxic effects, but the mechanism of action in resolving hairy leukoplakia is not
known. Again, hairy leukoplakia often recurs several weeks after successful podophyllin therapy.{ref22}
Topical therapy with retinoic acid (tretinoin) has been reported to resolve hairy leukoplakia. Retinoic acids
are known to inhibit EBV replication in vitro and induce epithelial cell differentiation. As with the antiviral
agents and podophyllin, hairy leukoplakia often recurs several weeks after successful retinoic acid
therapy.
Ablative therapy can also be considered for small hairy leukoplakia lesions. Cryotherapy has been
reported as successful but is not widely used.{ref23}
Institution of HAART, considered to be the standard care in the United States, is useful in eliminating the
lesions of oral hairy leukoplakia.
Superinfection with Candida can be addressed with medical therapy.

Consultations
Consultations with dentists, dermatologists, or infectious disease specialists may be in order depending
upon the underlying disease process resulting in oral hairy leukoplakia (OHL).

Diet

Diet may be as tolerated.

Medication
Medication Summary
The goals of pharmacotherapy are to reduce morbidity and prevent complications.

Medications
Antiviral agents
Nucleoside analogs initially are phosphorylated by viral thymidine kinase to eventually form a nucleoside
triphosphate.
Acyclovir (Zovirax)
Acyclovir has affinity for viral thymidine kinase and, once phosphorylated, causes DNA chain termination when
acted on by DNA polymerase. Patients experience less pain and faster resolution of lesions when used within 48
hours from onset of an outbreak. Acyclovir may prevent recurrent outbreaks. Early initiation of therapy is
imperative.
Valacyclovir (Valtrex)
Valacyclovir is a prodrug that is rapidly converted to the active drug acyclovir. It is more expensive but has a more
convenient dosing regimen than acyclovir.
Famciclovir (Famvir)
Famciclovir is a prodrug that when biotransformed into the active metabolite, penciclovir, may inhibit viral DNA
synthesis/replication.
Ganciclovir (Cytovene, Vitrasert)
Ganciclovir is indicated for CMV retinitis and the prevention of CMV infection in individuals who are HIV positive.
Foscarnet (Foscavir)

Foscarnet is indicated only for acyclovir-resistant mucocutaneous herpes simplex virus, which occurs almost
exclusively in individuals who are HIV positive.
Keratolytic agents
These agents cause cornified epithelium to swell, soften, macerate, and then desquamate.
Podophyllum resin (Pod-Ben-25, Podofin, Podocon-25)
The major active constituent, podophyllotoxin, is a lipid-soluble compound that easily crosses cell membranes.
Podophyllotoxin and its derivatives are potent cytotoxic agents that inhibit cell mitosis and deoxyribonucleic acid
(DNA). Cell division is arrested, and other cellular processes are impaired, gradually resulting in the disruption of
cells.
Podophyllum resin arrests mitosis in the metaphase; the active agent is podophyllotoxin; the type of podophyllum
resin used determines strength. American podophyllum contains one fourth the amount of Indian sources. It is used
in symptomatic OHL.
Antifungals
These agents reduce Candida superinfection.
Nystatin (Nilstat, Mycostatin, Nystex)
Nystatin is a fungicidal and fungistatic antibiotic obtained from Streptomyces noursei; it is effective against various
yeasts and yeastlike fungi. Nystatin changes the permeability of the fungal cell membrane after binding to cell
membrane sterols, causing cellular contents to leak. Treatment should continue until 48 hours after the
disappearance of symptoms. Nystatin is not absorbed significantly from the GI tract.
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